Menu
No results found.
Weekly Share Price & Valuation Overview
Dong-A ST Co., Ltd.
Dong-A ST Co., Ltd. develops, manufactures, and markets pharmaceutical products in South Korea and internationally. It offers various ethical drugs, including Closerin Cap for active pulmonary and extra-pulmonary tuberculosis; Dulastin PFS and Leucostim injection/PFS to treat neutropenia in patients receiving myelosuppressive chemotherapy; Eporon inj./PFS for anemia associated with chronic renal failure; Gemcit inj. to treat non-small cell lung, pancreatic, breast, bladder, and ovarian cancers; Gonadopin inj./PFS for infertility and anovulation; Growtropin II inj./AQ /cartridge to treat growth failure due to an inadequate secretion of growth hormone and idiopathic short stature; Mainta inj. for non-small cell lung cancer and malignant pleural mesothelioma; Monotaxel inj. to treat breast, non-small cell lung, prostate, head, and neck cancers, as well as gastric adenocarcinoma; Motilitone tab. for use in functional dyspepsia treatment; Stillen tab. to treat gastritis; Suganon tab./Sugamet XR tab. for type 2 diabetes mellitus; Terizidone tab to treat active pulmonary and extra-pulmonary tuberculosis; and Zydena tab. for erectile dysfunction treatment. The company also provides licensed-in and licensed-out drugs; and medical devices, which cover high-technology medical devices, custom-made products, and sets of artificial cardiac circuits for use in open-heart surgery. Dong-A ST Co., Ltd. was founded in 1932 and is headquartered in Seoul, South Korea.
- High gross margin (≥35%) suggests strong pricing power or cost control.
- Revenue growth ≥10% indicates solid top-line momentum.
- Quick ratio ≥1.0 indicates obligations can be met without inventory.
- Debt/EBITDA >4 — elevated leverage vs earnings capacity.
- Negative free cash flow — operations may rely on external financing.
- Market Cap Total equity value of the company (share price × shares outstanding).
- KRW 421.97B
- Enterprise Value Operating value: market cap + total debt − cash.
- KRW 674.70B
- Total Revenue (TTM) Sales over the last twelve months. May be estimated from revenue per share when inconsistent.
- KRW 724.59B
- Gross Profit (TTM) Revenue minus cost of goods sold over the last twelve months. Hidden for financial institutions or if redundant.
- KRW 345.24B
- EBITDA (TTM) Earnings before interest, taxes, depreciation and amortization (TTM). Hidden for financials or if implausible.
- KRW 16.93B
- Revenue per Share (TTM) Total revenue divided by shares outstanding (may be estimated).
- KRW 81.24K
- Dividend Yield Annual dividend ÷ share price. Reconciled using dividend per share when available.
- 1.52%
- Shares Outstanding
- 9.16M
- Float Shares
- 4.80M
- Implied Shares Outstanding
- 9.18M
- Operating Margin (TTM) Operating income ÷ revenue over the last twelve months (reconciled when possible).
-
-2.64%
- EBITDA Margin (TTM) Reconciled EBITDA ÷ revenue over the last twelve months (suppressed if EBITDA implausible/financials).
-
2.34%
- Gross Margin (TTM) Reconciled Strong Gross profit ÷ revenue over the last twelve months (reconciled when possible).
-
47.65%
- Profit Margin (TTM) Net income ÷ revenue over the last twelve months (reconciled when possible).
-
-0.11%
- ROA Return on assets: net income ÷ total assets.
-
-0.65%
- ROE Return on equity: net income ÷ shareholder equity.
-
-3.04%
- Revenue Growth Strong Year-over-year revenue growth.
-
17.20%
- Quick Ratio Adequate Liquid current assets ÷ current liabilities (ex-inventory).
- 1.19
- Debt to Equity Total debt ÷ shareholder equity; leverage.
- 0.69
- Total Cash Cash and equivalents.
- KRW 257.86B
- Total Debt Short + long-term interest-bearing debt.
- KRW 475.99B
- Net Debt Total debt − cash (negative = net cash).
- KRW 218.13B
- Debt / EBITDA Leverage relative to operating earnings; lower is safer.
- 28.11
- Operating Cash Flow (TTM) Cash generated by core operations (pre-capex).
- KRW 5.76B
- Free Cash Flow (TTM) Cash after capex; funds buybacks, dividends, and debt paydown.
- KRW -43.37B
- OCF Margin (TTM) Operating cash flow ÷ revenue (TTM).
-
0.80%
- FCF Margin (TTM) Free cash flow ÷ revenue (TTM).
-
-5.99%
- Cash Conversion (OpCF/EBITDA)
- 0.34
- Margins shown on a TTM basis. “Reconciled” = numerator ÷ TTM revenue for internal consistency.
- Cash Flow section is displayed only when figures are self-consistent (and hidden for financials).
Disclaimer: Information is compiled from publicly available sources and is subject to errors and omissions. It is provided as a guide only and does not constitute investment advice. Please do your own research.